Vincent Delorme

Dr. Vincent Delorme

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2017 in Science
Verified
Journal Article
Closed access
PDF file
NBNicolas Blondiaux
Nicolas Blondiaux
MMMartin Moune
Martin Moune
MDMatthieu Desroses
Matthieu Desroses
RFRosangela Frita
Rosangela Frita
MFMarion Flipo
Marion Flipo
NWNicolas Willand
Nicolas Willand
Countering TB prodrug resistance: The arsenal of antibiotics for treating tuberculosis (TB) contains many prodrugs, such as ethionamide, which need activation by normal metabolism to release their toxic effects. Ethionamide is potentiated by small molecules. Blondiaux et al. screened for more potent analogs and identified a lead compound called SMARt-420. This small molecule inactivates a TetR-like repressor, EthR2, and boosts ethionamide activation. SMARt-420 successfully promoted clearance of multidrug-resistant strains of Mycobacterium tuberculosis from the lungs of mice. Science , this issue p. 1206

12 March 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MWMinjeong Woo
Minjeong Woo
CWConnor Wood
Connor Wood
DKDoyoon Kwon
Doyoon Kwon
KPKyu-Ho Paul Park
Kyu-Ho Paul Park
GFGyorgy Fejer
Gyorgy Fejer
VDVincent Delorme
Vincent Delorme
Lung alveolar macrophages (AMs) are in the first line of immune defense against respiratory pathogens and play key roles in the pathogenesis of Mycobacterium tuberculosis (Mtb) in humans. Nevertheless, AMs are available only in limited amounts for in vitro studies, which hamper the detailed molecular understanding of host-Mtb interactions in these macrophages. The recent establishment of the self-renewing and primary Max Planck Institute (MPI) cells, functionally very close to lung AMs, opens unique opportunities for in vitro studies of host-pathogen interactions in respiratory diseases. Here, we investigated the suitability of MPI cells as a host cell system for Mtb infection. Bacterial, cellular, and innate immune features of MPI cells infected with Mtb were characterized. Live bacteria were readily internalized and efficiently replicated in MPI cells, similarly to primary murine macrophages and other cell lines. MPI cells were also suitable for the determination of anti-tuberculosis (TB) drug activity. The primary innate immune response of MPI cells to live Mtb showed significantly higher and earlier induction of the pro-inflammatory cytokines TNFα, interleukin 6 (IL-6), IL-1α, and IL-1β, as compared to stimulation with heat-killed (HK) bacteria. MPI cells previously showed a lack of induction of the anti-inflammatory cytokine IL-10 to a wide range of stimuli, including HK Mtb. By contrast, we show here that live Mtb is able to induce significant amounts of IL-10 in MPI cells. Autophagy experiments using light chain 3B immunostaining, as well as LysoTracker labeling of acidic vacuoles, demonstrated that MPI cells efficiently control killed Mtb by elimination through phagolysosomes. MPI cells were also able to accumulate lipid droplets in their cytoplasm following exposure to lipoproteins. Collectively, this study establishes the MPI cells as a relevant, versatile host cell model for TB research, allowing a deeper understanding of AMs functions in this pathology.

15 November 2017 in EMBO Reports
Verified
Journal Article
Closed access
PDF file
OSOk‐Ryul Song
Ok‐Ryul Song
CQChristophe J Queval
Christophe J Queval
RIRaffaella Iantomasi
Raffaella Iantomasi
VDVincent Delorme
Vincent Delorme
SMSabrina Marion
Sabrina Marion
PBPriscille Brodin
Priscille Brodin

4 May 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
MFMarion Flipo
Marion Flipo
RFRosangela Frita
Rosangela Frita
MBMarilyne Bourotte
Marilyne Bourotte
MMMaría S. Martínez-Martínez
María S. Martínez-Martínez
MBMarkus Boesche
Markus Boesche
NWNicolas Willand
Nicolas Willand
The sensitivity of Mycobacterium tuberculosis , the pathogen that causes tuberculosis (TB), to antibiotic prodrugs is dependent on the efficacy of the activation process that transforms the prodrugs into their active antibacterial moieties. Various oxidases of M. tuberculosis have the potential to activate the prodrug ethionamide. Here, we used medicinal chemistry coupled with a phenotypic assay to select the N-acylated 4-phenylpiperidine compound series. The lead compound, SMARt751, interacted with the transcriptional regulator VirS of M. tuberculosis , which regulates the mymA operon encoding a monooxygenase that activates ethionamide. SMARt751 boosted the efficacy of ethionamide in vitro and in mouse models of acute and chronic TB. SMARt751 also restored full efficacy of ethionamide in mice infected with M. tuberculosis strains carrying mutations in the ethA gene, which cause ethionamide resistance in the clinic. SMARt751 was shown to be safe in tests conducted in vitro and in vivo. A model extrapolating animal pharmacokinetic and pharmacodynamic parameters to humans predicted that as little as 25 mg of SMARt751 daily would allow a fourfold reduction in the dose of ethionamide administered while retaining the same efficacy and reducing side effects.

1 July 2017 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
JJJichan Jang
Jichan Jang
RKRyangyeo Kim
Ryangyeo Kim
MWMinjeong Woo
Minjeong Woo
JJJinsun Jeong
Jinsun Jeong
DPDa Eun Park
Da Eun Park
VDVincent Delorme
Vincent Delorme
New and improved treatments for tuberculosis (TB) are urgently needed. Recently, it has been demonstrated that verapamil, an efflux inhibitor, can reduce bacterial drug tolerance caused by efflux pump activity when administered in combination with available antituberculosis agents. The aim of this study was to evaluate the effectiveness of verapamil in combination with the antituberculosis drug candidate Q203, which has recently been developed and is currently under clinical trials as a potential antituberculosis agent. We evaluated changes in Q203 activity in the presence and absence of verapamil in vitro using the resazurin microplate assay and ex vivo using a microscopy-based phenotypic assay for the quantification of intracellular replicating mycobacteria. Verapamil increased the potency of Q203 against Mycobacterium tuberculosis both in vitro and ex vivo , indicating that efflux pumps are associated with the activity of Q203. Other efflux pump inhibitors also displayed an increase in Q203 potency, strengthening this hypothesis. Therefore, the combination of verapamil and Q203 may be a promising combinatorial strategy for anti-TB treatment to accelerate the elimination of M. tuberculosis .

16 January 2023 in Molecular Microbiology
Verified
Journal Article
Closed access
MCMaria Fernanda de Souza Costa
Maria Fernanda de Souza Costa
FPFilipe S, Pereira-Dutra
Filipe S, Pereira-Dutra
NDNathalie Deboosere
Nathalie Deboosere
SJSamuel Jouny
Samuel Jouny
OSOk‐Ryul Song
Ok‐Ryul Song
PBPriscille Brodin
Priscille Brodin